paclitaxel chemotherapy induced peripheralneuropathy
Conditions
Interventions
Treatment group:Precision Moxibustion Twelve Well Points+Mecobalamin
Sponsors
The Second Clinical College,Guangzhou University of Chinese Medicine University-town Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age 20-70 years old. (2) Patients with pathologically confirmed gynecologic malignancies treated with paclitaxel alone (including regular paclitaxel, paclitaxel liposome, and albumin paclitaxel) or in combination with chemotherapy. (3) After receiving at least one course of paclitaxel chemotherapy and developing symptoms of peripheral neuropathy. (4) No serious cardiac, hepatic or renal disorders and no history of diabetes. (5) No local skin breakdown. (6) Sign the informed consent form, voluntarily accept the treatment of this protocol, and adhere to and cooperate with the treatment during the observation cycle.
Exclusion criteria
Exclusion criteria: (1) Combination of peripheral neuropathy due to acute or post-acute phase of cerebrovascular disease, alcohol dependence, diabetes, malnutrition, and hypothyroidism. (2) Combined cellulitis and venous thrombosis in the extremities. (3) Infected and broken skin on the extremities. (4) Patients currently enrolled or enrolled in another clinical trial within 1 month prior to this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Neuropathy Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The European O-rganization for Reasearch and Treatment of Cancer-Quality of Life Questionnare-Core 30;Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity; | — |
Countries
China
Contacts
Public ContactCai Lin-er
The Second Clinical College,Guangzhou University of Chinese Medicine University-town Hospital
Outcome results
None listed